compound 9j

Compound 9j is a non-specific designation used in medicinal chemistry to identify the tenth compound in a synthesized series. The provided context describes two distinct molecules with this label. The first is a pyrimidine-bridged derivative of combretastatin A-4 (CA-4) that acts as a colchicine binding site inhibitor (CBSI). This molecule inhibits tubulin polymerization, disrupts tumor vasculature, and induces G2/M phase cell cycle arrest and apoptosis. It has shown potent anti-proliferative activity against cervical cancer (HeLa) cells and synergistic effects with cisplatin in xenograft models. The second molecule is a 1,2,3-triazole-incorporated 1,3,4-oxadiazole-triazine derivative that has demonstrated in vitro anticancer activity against prostate (PC3, DU-145), lung (A549), and breast (MCF-7) cancer cell lines. Some sources also link the designation to a Coixol derivative known as anti-inflammatory agent 55, which inhibits the NF-κB pathway.

Other names

anti-inflammatory agent 55pyrimidine-bridged CA-4 derivativeCoixol derivative